Liang Qiuman, Wang Siyi, Wang Beibei, Hong Yanyan
Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
School of Nursing, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Front Nutr. 2025 Jan 14;11:1488054. doi: 10.3389/fnut.2024.1488054. eCollection 2024.
To report the first and largest systematic review and meta-analysis of randomized controlled trials (RCT) to evaluated the efficacy and safety of post-discharge oral nutritional supplements (ONS) for patients with gastric cancer undergoing gastrectomy.
Systematic review and meta-analysis.
RCT which evaluated the efficacy and/or safety of post-discharge ONS for patients with gastric cancer undergoing gastrectomy.
We conducted a systematic literature retrieval via PubMed, Embase, Web of Science, and Cochrane until April, 2023 for relevant RCTs.
Outcomes of meta-analysis included absolute change of body weight, % change of body weight, absolute change of body composition, absolute change of laboratory parameters and adverse events. All the relevant data were analyzed by Review Manager 5.4.1 and Stata 15.1.
5 RCTs including 1,586 patients (804 in ONS group versus 782 in control group) were included for meta-analysis. The two groups were comparable in age, gender (male), weight at baseline, BMI at baseline, albumin at baseline, and hemoglobin at baseline. Meta-analysis revealed a significant lower absolute body weight loss (WMD: 0.75; 95% CI: 0.11, 1.40; = 0.02) and % body weight loss (WMD: 1.15; 95% CI: 0.20, 2.11; = 0.02) in the ONS group compared with the control (regular diet/dietary advice) group. Moreover, this study did not observe a significant difference between the two groups for adverse events rate (RR: 1.11; 95% CI: 0.81, 1.53; = 0.52).
ONS was significantly effective and safe in improving postoperative weight loss for patients with gastric cancer undergoing gastrectomy.
Identifier, CRD42023414678, https://www.crd.york.ac.uk/PROSPERO/.
报告首个也是规模最大的关于评估胃癌胃切除术后出院口服营养补充剂(ONS)疗效和安全性的随机对照试验(RCT)的系统评价和荟萃分析。
系统评价和荟萃分析。
评估胃癌胃切除术后出院ONS疗效和/或安全性的RCT。
我们通过PubMed、Embase、Web of Science和Cochrane进行了系统的文献检索,直至2023年4月以获取相关RCT。
荟萃分析的结果包括体重的绝对变化、体重变化百分比、身体成分的绝对变化、实验室参数的绝对变化和不良事件。所有相关数据均采用Review Manager 5.4.1和Stata 15.1进行分析。
纳入5项RCT进行荟萃分析,共1586例患者(ONS组804例,对照组782例)。两组在年龄、性别(男性)、基线体重、基线BMI、基线白蛋白和基线血红蛋白方面具有可比性。荟萃分析显示,与对照组(常规饮食/饮食建议)相比,ONS组的绝对体重减轻(加权均数差:0.75;95%置信区间:0.11,1.40;P = 0.02)和体重减轻百分比(加权均数差:1.15;95%置信区间:0.20,2.11;P = 0.02)显著更低。此外,本研究未观察到两组不良事件发生率之间存在显著差异(风险比:1.11;95%置信区间:0.81,1.53;P = 0.52)。
ONS对胃癌胃切除术后患者改善术后体重减轻具有显著疗效且安全。
标识符,CRD42023414678,https://www.crd.york.ac.uk/PROSPERO/ 。